Physician profile
Michael Johnson
NPI 1326132408
$5,430.29
in general payments reported to CMS, 2019-2025
43 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2022: $643 · 2023: $796 · 2024: $1,634 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,298.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,268.30 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $583.39 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $441.21 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $310.28 | 2022-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $306.04 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $267.42 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $216.68 | 2025 | Fanapt, Hetlioz |
| Paratek Pharmaceuticals, INC. | $198.94 | 2021-2024 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $168.02 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Glaxosmithkline, LLC. | $127.62 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $122.07 | 2021-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $118.37 | 2023-2025 | Seglentis, Zoryve, Livalo |
| Lundbeck LLC | $113.78 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $83.50 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.37 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.